Blog
RSS FeedPosted by Michael Wonder on 15 Apr 2021
Medicare Benefits Schedule Electrocardiogram Review Committee – appointment of Committee Members
15 April 2021 - The Medicare Benefits Schedule Review Committee was established in March 2021 to review electrocardiogram items introduced on ...
Posted by Michael Wonder on 12 Apr 2021
Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision-making
12 April 2021 - This research aims to explore how often NICE uses immature overall survival data to inform reimbursement ...
Posted by Michael Wonder on 06 Apr 2021
Decision to widen access to secukinumab for psoriatic arthritis and ankylosing spondylitis
1 April 2021 - PHARMAC is pleased to announce a decision to widen funded access to secukinumab (Cosentyx) for the ...
Posted by Michael Wonder on 06 Apr 2021
Development of an international template to support patient submissions in health technology assessments
1 April 2021 - The objective was to develop an international template to support patient submissions in health technology assessments. ...
Posted by Michael Wonder on 17 Mar 2021
Mythbusting PHARMAC
17 March 2021 - The agency is seeking to dispel some misunderstandings about what it does and how it does ...
Posted by Michael Wonder on 17 Mar 2021
PHARMAC’s drug switch
17 March 2021 - PHARMAC's generic drug swap for epilepsy treatment saved $30 million over five years. But for some ...
Posted by Michael Wonder on 08 Mar 2021
Pacific pharmacists want inclusion on PHARMAC review
6 March 2021 - The President of the Pacific Pharmacists’Association, Kasey Brown, says a review of New Zealand’s drug buying ...
Posted by Michael Wonder on 08 Mar 2021
Is the Department of Health guilty of abusing its monopsonistic power?
8 March 2021 - In these times of heightened sensitivities, is it time the folks in Canberra got called out ...
Posted by Michael Wonder on 08 Mar 2021
More startling revelations from the Public Summary Document for upadacitinib monohydrate (Rinvoq)
8 March 2021 - Take a seat before reading any further. ...
Posted by Michael Wonder on 08 Mar 2021
Jacinda Ardern responds to heartfelt plea from PHARMAC funding advocate Malcolm Mulholland
8 March 2021 - Prime Minister Jacinda Ardern has responded to a heartfelt plea by Malcolm Mulholland, a man advocating ...
Posted by Michael Wonder on 07 Mar 2021
PHARMAC does a great job, but it's losing the PR battle hands down
6 March 2021 - With each major change of government in recent years, PHARMAC has been required either to list ...
Posted by Michael Wonder on 01 Feb 2021
Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries
29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due ...
Posted by Michael Wonder on 31 Jan 2021
Evaluation of the impact of patient input in health technology assessments at NICE
29 January 2021 - Accounts of patient experiences are increasingly used in health technology assessment processes. However, we know little about ...
Posted by Michael Wonder on 27 Jan 2021
On the role of cost effectiveness thresholds in health care priority setting
25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...
Posted by Michael Wonder on 24 Jan 2021
Creating a patient and community advisory committee at the Canadian Agency for Drugs and Technologies in Health
22 January 2021 - In recognition of patients’ roles using, and contributing to, a publicly funded health system, the Canadian Agency ...